Algan O, Hanks G E, Shaer A H
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):925-30. doi: 10.1016/0360-3016(95)00226-4.
To determine whether retrograde urethrogram, or the combination of computed tomography (CT) scan/retrograde urethrogram is more accurate for locating the magnetic resonance imaging (MRI) designated prostatic apex, and to determine whether patients treated in our department with CT/urethrogram are receiving the prescribed minimal dose to the MRI identified prostatic apex.
Seventeen patients with early stage prostate cancer were enrolled in a prospective study to determine the location of the prostatic apex. All of the patients agreed to undergo MRI in addition to retrograde urethrogram, and CT of the pelvis for three dimensional (3D) treatment planning. The prostatic apex was identified on each of the studies and measured from a reference point (the most superior portion of the pubic symphysis). The location of the prostatic apex as measured by retrograde urethrogram alone and by CT/urethrogram was compared to the location of the prostatic apex as measured by MRI. Because of MRI's ability for multiplanar capabilities, and high soft tissue contrast in the region of the prostate, it was assumed to be more accurate for identifying the location of the prostatic apex, and was used as the gold standard.
The location of the prostatic apex as determined by the urethrogram alone was on average 5.8 mm caudad to the location on MRI (p = 0.012), while the location of the prostatic apex as determined by CT/urethrogram was 3.1 mm caudad to the location on MRI (p = 0.150). If the prostatic apex is defined at 12 mm instead of 10 mm above the urethrogram tip, the statistically significant difference between the urethrogram and the MRI is no longer present. Based on these results, all 17 patients received the minimum prescribed dose to the prostatic apex.
CT/urethrogram correlates better with the location of the MRI determined prostatic apex, than does the urethrogram alone. Locating the prostatic apex 12 mm above the urethrogram tip better localizes the prostatic apex, while also avoiding the error that can potentially lead to a geographic miss. This in fact assures that all of our patients receive the minimum prescribed dose to this critical site of extraprostatic extension, while also decreasing the amount of normal tissue that is included in the treatment volume.
确定逆行尿道造影,或计算机断层扫描(CT)/逆行尿道造影联合检查在定位磁共振成像(MRI)所确定的前列腺尖时是否更准确,并确定在我院接受CT/尿道造影检查的患者对MRI所确定的前列腺尖是否接受了规定的最小剂量照射。
17例早期前列腺癌患者纳入一项前瞻性研究以确定前列腺尖的位置。所有患者均同意除逆行尿道造影外还接受MRI检查,以及骨盆CT检查以进行三维(3D)治疗计划。在每项检查中确定前列腺尖,并从一个参考点(耻骨联合最上部)进行测量。将单独通过逆行尿道造影和CT/尿道造影测量的前列腺尖位置与通过MRI测量的前列腺尖位置进行比较。由于MRI具有多平面成像能力以及前列腺区域的高软组织对比度,假定其在识别前列腺尖位置方面更准确,并将其用作金标准。
单独通过尿道造影确定的前列腺尖位置平均比MRI上的位置靠尾侧5.8 mm(p = 0.012),而通过CT/尿道造影确定的前列腺尖位置比MRI上的位置靠尾侧3.1 mm(p = 0.150)。如果将前列腺尖定义在尿道造影尖端上方12 mm而不是10 mm处,则尿道造影与MRI之间的统计学显著差异不再存在。基于这些结果,所有17例患者均接受了前列腺尖规定的最小剂量照射。
与单独的尿道造影相比,CT/尿道造影与MRI所确定的前列腺尖位置的相关性更好。将前列腺尖定位在尿道造影尖端上方12 mm处能更好地定位前列腺尖,同时避免可能导致靶区遗漏的误差。这实际上确保了我们所有患者对前列腺外扩展的这个关键部位接受规定的最小剂量照射,同时也减少了治疗体积中包含的正常组织量。